Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,462 total articles
Akita Drilling's purchase of Fox Drilling meaningfully expands its operational footprint in North America. The combination should drive higher utilization and revenue optionality; given a $147M market cap and depressed share price versus the 52-week high, there's a tradeable long with defined risk. This idea lays out entry, stop, targets, catalysts…
Ironwood is a small-cap biotech trading at bargain multiples backed by solid LINZESS economics and meaningful free cash flow. The stock is fundamentally a call on the company executing and advancing a second Phase 3 apraglutide trial requested by regulators. If the company proves the program is on track, the re-rating can be substantial; failure or…
OR Royalties reported Q3 deliveries of 20,237 GEOs and $90.2M of revenue with a cash margin of 96.8%, left $76.7M of cash on the balance sheet, and still has significant available lending capacity. The stock trades at $34.47, well below a 52-week high of $48.06; we see tactical upside to $40.00 on continued GEO delivery growth, accretive small acqu…
dLocal's rapid TPV growth and exceptional net retention argue that recent margin compression is the byproduct of scaling into large enterprise flows and competitive pricing, not a permanent structural decline. At a $4.1B market cap and $14.53 stock price, the risk/reward favors a long, with a clear entry at $14.53, stop at $11.50 and a target of $2…
West Pharmaceutical (WST) is a well-capitalized, cash-generative supplier of containment and delivery systems for injectables. Recent dynamics - stronger HVP uptake, biopharma exposure, and regulatory-driven Annex 1 upgrades - support continued revenue and margin improvement. Valuation is rich (P/E ~46, EV/EBITDA ~28.8) so this is a buy with measur…
AvePoint is showing signs of durable cash generation and getting a direct demand lift from enterprises scrambling to govern AI. At a market cap just above $3.0B and free cash flow of $100.2M, the stock offers a mid-term trade with defined risk controls as sentiment and fundamentals drift higher.
FMAO looks cheap for a regional with $3.4B+ in assets, a $487M market cap, and improving profitability. Rising net interest margin (industry tailwinds plus local loan growth), a history of dividend increases and a conservative balance sheet create room for a re-rate to a mid-teens P/E. Entry at $35.40, target $42.00, stop $31.00 for a long-term (18…
Marvell's investor day on 10/06/2026 reset expectations: FY2028 revenue guidance was raised to $20B and management disclosed an aggressive multi-year plan toward $70-90B in sales by FY2031. The stock is extended but supported by real backlog and strategic partnerships. This trade idea lays out a mid-term swing: buy into momentum with a stop below s…
Rocket Lab (RKLB) is showing improving top-line momentum, bullish technicals and a low-debt balance sheet while preparing transformational M&A and product catalysts. We outline a concrete trade: entry at $74.50, target $95.00, stop loss $64.00 over a mid-term horizon (45 trading days). The trade balances upside from launch cadence, Space Systems gr…
Energizer's combination of strong free cash flow ($150.6M), a healthy dividend yield (~5.6%), and modest leverage argues for upside from the current $21.59. We lay out an actionable long trade with precise entry, stop and target, catalysts to watch, and balanced risks.
Universal Health Realty Income Trust (UHT) yields ~8.1% and offers an income-first play with signs of stabilization: recent dividend increases, positive free cash flow of roughly $48M, and a market cap near $520M. Balance-sheet leverage and exposure to healthcare operating risk cap upside but current valuation and technicals provide a clear risk/re…
Black Stone Minerals (BSM) is showing renewed distribution growth backed by rising production and targeted acreage deals. At $14.69 the unit yields roughly 8.7% on the current quarterly payout, trades at an attractive EV/EBITDA ~10.3x, and offers a free-cash-flow yield north of 6%. That combination makes BSM a buyable name for a mid-term income tra…
Eli Lilly has built a rare position of strength in obesity and diabetes drugs, but that dominance carries valuation risk and exposure to payor pushback and competitive launches. We outline a short trade with a clear entry, stop and target and explain the fundamental and catalyst-driven path to a meaningful pullback over the next 180 trading days.
Lonza (LZAGY) looks like a buy here for investors who believe recent weakness reflects phasing and timing of capacity ramps rather than a durable hit to return on capital. The company sits in expanding CDMO and cell & gene end markets; technicals are constructive and market cap ($48.5B) already prices a mixed near-term outlook. Trade plan: enter $6…
International Seaways (INSW) is trading near $116 after a torrid move driven by record tanker spot rates. The company's balance sheet and cash generation are strong, but the market is pricing in persistent ultra-high rates. We lay out a tactical short trade: entry $116.42, stop $126.00, primary target $95.00 (mid-term), with a deeper target at $70 …
Progressive (PGR) looks like a measured long: attractive valuation, strong economics (ROE 34%), and durable distribution that benefits from AI-driven underwriting and claims automation. Enter around $212.05, stop at $200.00, target $245.00 over a 180 trading-day horizon.
BP is showing tangible signs of faster de-leveraging, portfolio high-grading and consistent earnings beats under new leadership. At $45.09 the stock is trading near the middle of its 52-week range with a 4.5% yield, light short-interest coverage and improving analyst revisions. This trade targets near-term re-rating toward previous highs while prot…
American Express has pulled back amid cyclical headwinds and investor rotation. The company’s high-margin network, affluent cardholder base, and recurring fee income make this a tactical long: enter on weakness, size for a bounce and hold for 180 trading days if fundamentals remain intact. Clear entry, stop and target are provided with risk control…
Micron's results and guidance show one thing clearly: memory is no longer a single commodity market. High-bandwidth memory and data-center SSDs tied to AI are commanding outsized revenue and margin contribution. This trade idea buys a pullback to capture continued AI-driven strength while protecting capital against cyclical price swings and aggress…
Jeronimo Martins is highly exposed to Poland via its Biedronka chain. A slowing Polish consumer, rising promotional intensity, and margin pressure create a pathway for downside over the next 45-180 trading days. This is a tactical short with defined entry, stop and target levels.
Textron mixes steady commercial aviation sales, defense programs, and industrial cash flow. At roughly $13.0B market cap, a PE near 14 and EV/EBITDA under 10 look reasonable for a business generating ~$759M in free cash flow. I recommend a tactical long with precise entry, stop and target aimed at capturing a re-rating and backlog conversion over t…
The Hartford is trading at a single-digit P/E, generates meaningful free cash flow and has a new $4.2 billion buyback authorization that should materially reduce float and support EPS. We propose a mid-term long trade to capture a valuation re-rate and buyback execution, while respecting catastrophe and underwriting risks with a defined stop.
PayPal trades at a sub-10x P/E with $6.6B in free cash flow, a $46.7B market cap and positive technicals. I lay out an actionable swing trade with entry, stop and target levels, plus the catalysts and risks that determine whether this remains a buy.
ASML’s unique position in EUV lithography, expanding manufacturing capacity and strong analyst forecasts for Q3 and FY revenues create a compelling pre-earnings trade. Valuation is rich, but the business fundamentals and technical momentum support a mid-term long into earnings with disciplined risk control.
Hormel Foods yields ~5.8% and trades close to its 52-week low after a top-line miss and lowered sales guidance. The business still throws off strong free cash flow, has limited leverage and is buying growth in foodservice with a $1.055B Brakebush deal. This trade targets income and upside recovery over 180 trading days with a defined entry, stop an…
